ViiV Venture Expands To Include Shionogi | Chemical & Engineering News
Volume 90 Issue 45 | p. 13 | Concentrates
Issue Date: November 5, 2012

ViiV Venture Expands To Include Shionogi

Department: Business
Keywords: HIV, AIDS, pharmaceuticals, joint venture

ViiV Healthcare, a three-year-old HIV drug venture between GlaxoSmithKline and Pfizer, is restructuring to include Japan’s Shionogi as a partner. Since mid-2010, Shionogi has had a joint venture with ViiV to develop dolutegravir and other early-stage integrase inhibitors. In exchange for its development and commercialization rights to the compounds, Shionogi will get a 10% ownership stake in ViiV. GSK’s share in ViiV will decrease from 85.0% to 76.5%; Pfizer’s will fall from 15.0% to 13.5%. ViiV anticipates filing for regulatory approval of dolutegravir before the end of the year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment